

PATENT COOPERATION TREATY 9/622101

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY


PCT

WRITTEN OPINION

(PCT Rule 66)

To:

VOSSIUS & PARTNER
VOSSIUS & PARTNER
Postfach 86 07 67
D-81634 München
ALLEMAGNE



Date of mailing
(day/month/year)

17.01.2000

Applicant's or agent's file reference

B 3270 PCT

REPLY DUE

within 3 month(s)
from the above date of mailing

International application No.

PCT/EP99/00945

International filing date (day/month/year)

12/02/1999

Priority date (day/month/year)

13/02/1998

International Patent Classification (IPC) or both national classification and IPC

C12P21/00

Applicant

MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC

1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.
2. This opinion contains indications relating to the following items:
 - I ☒ Basis of the opinion
 - II ☐ Priority
 - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - IV ☐ Lack of unity of invention
 - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI ☐ Certain document cited
 - VII ☐ Certain defects in the international application
 - VIII ☐ Certain observations on the international application
3. The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also: For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.
4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: **13/06/2000.**

Name and mailing address of the international preliminary examining authority:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer / Examiner

Marie, A

Formalities officer (incl. extension of time limits)

Schou, S

Telephone No. +49 89 2399 8843



WRITTEN OPINION

International application No. PCT/EP99/00945

I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*):

Description, pages:

1-64 as originally filed

Claims, No.:

1-38 as originally filed

Drawings, sheets:

1/7-7/7 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-38 (Yes)
Inventive step (IS)	Claims	1-38 (No)
Industrial applicability (IA)	Claims	1-38 (Yes)

2. Citations and explanations

separate sheet

1. The problem underlying the present application, the so-called "bottle-neck" of AZT activation, has already been described in the following publications:

PNAS, 1998, 95, 14045-14050 (D1),

Biochemistry, 1998, 37, 3677-3686 (D2),

Nature Structural Biology, 1997, 4/8, 601-604 (D3) and

Nature Medicine, 3/8, 1997, 836-837 (D4).

D1-D4 also describe the structural modifications occurring in the thymidylate kinase during the phosphorylation of AZT and they elucidate the function and the importance of the LID region, the P-loop or the amino acid in position 105 (see for instance, **D1**, page 14046, right column, 10 lines from the bottom) by comparison between the yeast or human and *E. coli* enzyme.

Furthermore, **D3** suggests on page 603 (middle column) the modification of the thymidylate kinase, so that it phosphorylates AZTMP more effectively.

2. Therefore, not only the problem was described in the prior art, as demonstrated by **D1-D4**, but also the solution was suggested and even more the molecular basis for said suggestion was explained.
As a consequence, the subject-matter of the present application cannot be considered as being based on an inventive concept and, hence, cannot give rise to claims allowable under Article 33.3 PCT.
3. The methods of claims 29 and 30 cannot be considered as inventive (Article 33.3 PCT), since they are only based on the well-known action of thymidylate kinases and are not depending on the modified kinases of the present application (Article 33.3 PCT).
4. Inhibitors, which are **obtainable** by the method of claims 31 or 32, but which have been obtained by other means, are already known. They could be for instance, a substrate analog, such as TP_5A . Therefore, claim 35 does not seem to be inventive (Article 33.3 PCT).
5. Rejection of the present application for lack of inventive step (Article 33.3 PCT) has to be expected.



✉ EPA/EPO/OEB
D-80298 München
☎ +49 89 2399-0
TX 523 656 eprmu d
FAX +49 89 2399-4465

**Europäisches
Pat ntamt**

Generaldirektion 2

**European
Pat nt Office**

Directorate General 2

**Office uropéen
des br vets**

Direction Générale 2

Correspondence with the EPO on PCT Chapter II demands

In order to ensure that your PCT Chapter II demand is dealt with as promptly as possible you are requested to use the enclosed self-adhesive labels with any correspondence relating to the demand sent to the Munich Office.

One of these labels should be affixed to a prominent place in the upper part of the letter or form etc. which you are filing.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 21/00, 21/08, C12N 15/63, 1/11, 1/19, 1/21, 5/10, C07K 16/00, A61K 38/43, 39/00, C07K 14/245, 14/39, 14/435	A3	(11) International Publication Number: WO 99/41404 (43) International Publication Date: 19 August 1999 (19.08.99)
(21) International Application Number: PCT/EP99/00945 (22) International Filing Date: 12 February 1999 (12.02.99) (30) Priority Data: 98102546.3 13 February 1998 (13.02.98) EP (71) Applicant (for all designated States except US): MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN [DE/DE]; Berlin (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): GOODY, Roger, S. [GB/DE]; Hamackstrasse 61b, D-44139 Dortmund (DE). KONRAD, Manfred [DE/DE]; Zur Scharfmühle 74, D-37083 Göttingen (DE). LAVIE, Arnon [DE/DE]; Hamackstrasse 61, D-44139 Dortmund (DE). REINSTEIN, Joachim [DE/DE]; Plauener Strasse 54, D-44139 Dortmund (DE). SCHLICHTING, Ilme [DE/DE]; Redtenbacher Strasse 30, D-44139 Dortmund (DE). (74) Agent: VOSSIUS & PARTNER; Postfach 86 07 67, D-81634 München (DE).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 28 October 1999 (28.10.99)
(54) Title: NOVEL MEANS AND METHODS FOR THE PREPARATION AND ACTIVATION OF NUCLEOSIDE AND NUCLEOTIDE BASED DRUGS		
(57) Abstract <p>Described are novel means and methods for the preparation and activation of nucleoside and nucleotide based drugs. In particular, a method for the production of a polypeptide having or having enhanced kinase activity for a nucleoside or nucleotide analog is provided and polypeptides obtainable by said method. Described are also polynucleotides and vectors encoding said polypeptide obtainable by the method of the invention as well as to host cells transformed therewith. Furthermore, antibodies against said polypeptide are provided and pharmaceutical and diagnostic compositions as well as kits comprising proteins having kinase activity for a nucleoside or nucleotide analog or their encoding polynucleotides or vectors. Furthermore, the use of the before described proteins, polypeptides, polynucleotides, vectors and antibodies is provided for the preparation of pharmaceutical compositions for treating, preventing and/or delaying a disease related to viral infection or cancer. In addition, a method for identifying inhibitors of nucleoside or nucleotide kinases is described and methods for identifying nucleoside or nucleotide based prodrugs employing the above mentioned polypeptides, polynucleotides, vectors and host cells. Also provided are compounds identifiable by said methods as well as pharmaceutical and diagnostic compositions comprising said inhibitors. Moreover, the use of proteins and polypeptides having nucleoside or nucleotide kinase activity or their encoding polynucleotides or vectors is described for the preparation of nucleoside or nucleotide phosphates or analogs and derivatives thereof.</p>		